A double-blind, sham-controlled, randomized Phase 2 study to determine safety and preliminary efficacy of intradiscally injected BRTX-100 for patients with cCDP
Latest Information Update: 05 Mar 2025
At a glance
- Drugs BRTX 100 (Primary)
- Indications Back pain; Intervertebral disc degeneration
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2025 New trial record
- 24 Feb 2025 According to a BioRestorative Therapies, Inc media release, U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BRTX-100, for the treatment of chronic cervical discogenic pain (cCDP).